Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + SHR6390 in HER2-positive Metastatic Breast Cancer
NCT03993964Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of dalpiciclib in breast cancer, sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate up to 100 months. Status: unknown.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03993964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03993964.